Lupus Foundation of America Statement on Successful Results of Phase IIB Clinical Trial of Voclosporin
Trial results offer hope of a more effective and tolerable treatment option to manage lupus-related kidney disease.
Today Aurinia Pharmaceutical Company announced positive top-line results of a Phase IIB clinical study of voclosporin, a potential new therapy option for people with active lupus nephritis (lupus-related kidney disease). The study met its primary endpoint of achieving complete remission in a statistically significant number of study participants who received voclosporin. More details about this study are available through the company’s news release.
Sandra C. Raymond, President & Chief Executive Officer of the Lupus Foundation of America said the results of this study are a very positive development for people with lupus-related kidney disease.
“The results of this trial are welcomed and exciting news for people with lupus and their doctors who are eager to have more tolerable and effective treatment options. Lupus-related kidney disease is one of the most serious and potentially life-threatening complications of lupus, affecting up to 60 percent of people with this autoimmune disease.
“This trial of voclosporin is the first trial of a potential treatment for active lupus nephritis to reach its primary endpoint, offering hope to individuals with lupus that an improved quality of life can soon be achieved. We are excited for the potential that the data from this study represents and we are eager to learn more details of additional analysis as they become available.
“We look forward to the timely commencement of a Phase III trial; and, should the findings confirm this study, the addition of this regimen to the arsenal of treatments available to people who have waited far too long for medicines that improve the quality of their lives.”
The Lupus Foundation of America will continue to monitor developments with this trial and communicate information to our constituents as it becomes available.
Duane Peters, firstname.lastname@example.org, 202-349-1145
Lupus is an unpredictable and misunderstood autoimmune disease that ravages different parts of the body. It is difficult to diagnose, hard to live with and a challenge to treat. Lupus is a cruel mystery because it is hidden from view and undefined, has a range of symptoms, strikes without warning, and has no known cause and no known cure. Its health effects can range from a skin rash to a heart attack. Lupus is debilitating and destructive and can be fatal, yet research on lupus remains underfunded relative to diseases of similar scope and devastation.
About the Lupus Foundation of America
The Lupus Foundation of America is the only national force devoted to solving the mystery of lupus, one of the world’s cruelest, most unpredictable and devastating diseases, while giving caring support to those who suffer from its brutal impact. Through a comprehensive program of research, education, and advocacy, the Foundation leads the fight to improve the quality of life for all people affected by lupus. Learn more about lupus, Lupus Science & Medicine Journal and the Lupus Foundation of America at lupus.org. For the latest news and updates, follow us on Twitter and Facebook.